- Home
- LILA vs GPCR Comparison
LILA vs GPCR Comparison
Compare LILA & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILA
- GPCR
- Stock Information
- Founded
- LILA 2017
- GPCR 2016
- Country
- LILA Bermuda
- GPCR United States
- Employees
- LILA N/A
- GPCR N/A
- Industry
- LILA Cable & Other Pay Television Services
- GPCR
- Sector
- LILA Telecommunications
- GPCR
- Exchange
- LILA Nasdaq
- GPCR Nasdaq
- Market Cap
- LILA 1.1B
- GPCR 1.1B
- IPO Year
- LILA N/A
- GPCR 2023
- Fundamental
- Price
- LILA $4.91
- GPCR $21.76
- Analyst Decision
- LILA Buy
- GPCR Strong Buy
- Analyst Count
- LILA 2
- GPCR 8
- Target Price
- LILA $7.90
- GPCR $79.29
- AVG Volume (30 Days)
- LILA 729.9K
- GPCR 755.1K
- Earning Date
- LILA 05-07-2025
- GPCR 05-08-2025
- Dividend Yield
- LILA N/A
- GPCR N/A
- EPS Growth
- LILA N/A
- GPCR N/A
- EPS
- LILA N/A
- GPCR N/A
- Revenue
- LILA $4,441,000,000.00
- GPCR N/A
- Revenue This Year
- LILA $3.30
- GPCR N/A
- Revenue Next Year
- LILA $3.11
- GPCR N/A
- P/E Ratio
- LILA N/A
- GPCR N/A
- Revenue Growth
- LILA N/A
- GPCR N/A
- 52 Week Low
- LILA $4.26
- GPCR $13.22
- 52 Week High
- LILA $10.82
- GPCR $62.74
- Technical
- Relative Strength Index (RSI)
- LILA 42.45
- GPCR 39.75
- Support Level
- LILA $4.83
- GPCR $22.09
- Resistance Level
- LILA $5.18
- GPCR $24.98
- Average True Range (ATR)
- LILA 0.24
- GPCR 1.64
- MACD
- LILA 0.02
- GPCR -0.54
- Stochastic Oscillator
- LILA 52.29
- GPCR 4.64
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.